Recently, we demonstrated that GXMGal inhibits Th17 activation [20] from RA patients and in the present study we confirm and extend our previously published data by demonstrating that the inhibition of Th17 was related to the inhibition of cytokines such as IL-21, IL-22 and IL-23. This evidence concerns the gene IL22 and rheumatoid arthritis.